Register now
Nordic Life Science Days 2016
14-15 september 2016
Waterfront, Stockholm, Sweden
© 2020 Bionordic. All Rights Reserved
Nordic Life Science Days 2016
14-15 september 2016
Waterfront, Stockholm, Sweden
© 2020 Bionordic. All Rights Reserved
This NLSDays 2021 Pre-Event will be a private, by-invitation only event. Investors and selected companies will experience a full-day program alongside relevant industry and financial parties. The day will include interactive workshops and company pitches.
From 1st April 2021, company presentations will be available on-demand in the following categories:
We are 27 million-strong, with shared values of openness, trust, sustainability, and equality, making the Nordics the perfect setting for partnerships & investments. In this session, we celebrate our Nordic Region with a Keynote by Cytiva CEO, Emmanuel Ligner, and a showcase of our 2021 Flagships, selected for their personal contribution to Nordic values & success. It is by coming together as a unified region that we are a greater force to be reckoned with globally – and we can see why when we take a look at what we each contribute nationally:
Moderator(s): Ms. Helena Strigård - Director General, SwedenBIO
Speaker(s):
Mr. Olivier Duchamp - Managing Director, NLSDays - NLS Invest
Ms. Helena Strigård - Director General, SwedenBIO
Mr. Emmanuel Ligner - CEO & President at Cityva (former GE Healthcare Life Sciences)
Mr. Gudmundur Fertram Sigurjonsson - Founder, President & CEO, Kerecis
Dr. Rafiq Hasan - CEO, ExACT Therapeutics
Mr. Erik Gatenholm - CEO and Co-Founder, Cellink
Dr. Jacqueline Ameri - CEO, Pancryos
Ms. Kaisa Helminen - Chief Operating Officer, Aiforia Technologies
The Nordic countries hold a unique position. With decades worth of health data covering more than 27 million people, we have the possibility to become a world-leading health innovation hub for the benefit of all individuals, patients, and global society. However, in order to realize this ambition, we must cooperate to better align, integrate, and use our health data in a protected and patient-centric way that also supports industry participation. In turn, industry holds a reciprocal requirement to protect our data, and to articulate & address their role in creating societal value. If we open up to greater collaboration, we can learn from each other and overcome the challenges together. In this session, leaders from across the Nordic Region and life science ecosystem will share their views on successful collaboration models related to health data as a driver for innovation and development, with recommendations for joint action.
Moderator(s): Mr. Bogi Eliasen - Director of Health, Copenhagen Institute for Futures Studies
Speaker(s):
Mr. Bogi Eliasen - Director of Health, Copenhagen Institute for Futures Studies
Ms. Niina Aagaard - Chief Operating Officer, Nordic Innovation
Ms. Louise Rosenlund Nielsen - Head of International Development & Partnerships, CopCap
Dr. Mervi Aavikko - Project Manager FinnGen, University of Helsinki
Ms. Rajji Mehdwan - Head of People and Culture, Roche
Dr. Nikolai Brun - Chair HMA-EMA Taskforce on Big Data
Dr. Frederik Knud Nielsen - Strategic Pipeline Lead, Nordics, Novartis
Dr. Lars Lindsköld - Portfolio manager, Sweper / Swelife
The human microbiome is considered a counterpart to the human genome, with the number of genes in our microbiome outnumbering the genes in our genome by 100 to 1. The microbiome is a set of highly interactive species which is heavily impacted by its surrounding environment and whose balance is vital to human health.
Today, gut microbiome is at the leading edge of scientific research across more than 170 countries. In this session, “Microbiome: the New Genetics?”, hosted by the Greater Copenhagen Microbiome Signature Project, we will hear from some of the world’s leaders on the current developments within microbiome research, such as host-microbe interactions and their implications on disease progression and treatment, where opportunities and challenges exist in translating proof-of-concept studies in animal models to clinical trials, and how research can transition from academia to industry to result in improved therapies and better therapeutic outcomes for patients. The discussions will further shed light on how the Nordics can play a key role in moving the field forward.
Moderator(s): Dr. Eric De La Fortelle - Venture Partner, Seventure Partners
Speaker(s):
Dr. Eric De La Fortelle - Venture Partner, Seventure Partners
Dr. Paul Ross - Director, APC Microbiome Ireland
Ms. Sarah Lidé - Senior Strategy & Project Manager, Medicon Valley Alliance
Dr. Gianfranco Grompone - Chief Scientific Officer, BioGaia
Ms. Sarah Lidé - Senior Strategy & Project Manager, Medicon Valley Alliance
Dr. Paul Ross - Director, APC Microbiome Ireland
Dr. Mirjam Mol-Arts - Chief Science and Medical Officer, Ferring Pharmaceuticals
Dr. Henrik Bjørn Nielsen - Chief Scientific Officer, Clinical Microbiomics
We are in the midst of a new era, one in which the impacts on our global health and safety are increasingly evident. While the world looks different than it did one year ago, we have also learned how to operate in new ways and have been tested to think outside of every known box. What should we retain from these learnings – and which changes should we keep – as we find ourselves in a post-pandemic normal?
Our life science industry is full of exciting innovations, yet many companies are wary of shouting about their accomplishments, culturally and within a strictly regulated environment. At the same time, the world won’t notice your company unless you provide compelling information about who you are and how you are changing the game. It’s vital that potential stakeholders understand that you are developing the best solution to the problems they face. Therefore, you must be able to present them with the bold vision behind what your innovation means to the market, alongside a relevant brand story. Join us to learn about the power of branding in differentiating you from your competitors and in influencing customer perceptions through storytelling.
From 1st April 2021, company presentations will be available on-demand in the following categories:
Innovation & technology are the beating heart of human progress, starting the moment we begin to think and act differently in companies & investments. Our session will begin with a Keynote from the Head of the Life Science Division at the European Investment Bank (EIB), one of the largest supporters of European innovation, as well as one of the largest venture capital providers via the European Investment Fund (EIF). For Europe and the Nordics to remain globally competitive, the EIB’s mandate is clear: go digital, go green, and take the risk.
In the first half of our session, we will tackle the Elevator Pitch, with a ‘twist’. As a start-up, it is often expected that an elevator pitch is ready to deliver on-demand. How do the Pros do it? Meet our team of financial experts across four major funds. Each is here to tell you a bit about their vision, strategy, and ideal fit by offering up their ”Reverse-Elevator Pitch: Investor to SME.”
In 2015, NY Times quoted, “There are more CEOs named John than female CEOs.” Five years later, we see a growing number of female partners in VC firms and corporate leadership roles, but is it enough? In the second half of this session, we have put together a leading panel of female experts who will address the role of gender in financing and corporate development, including how women think and invest differently and how leadership diversity can increase a company’s valuation. Our panel will also tackle other topics, all geared towards helping you hunt wisely for intelligent capital and maximize your chances of success. For example, did you know an investor’s rejection can be a good thing? Expect an interactive dialogue & come with questions!
Moderator(s): Dr. Sonia Benhamida - Senior Vice President Healthcare, DNB
Speaker(s):
Dr. Sonia Benhamida - Senior Vice President Healthcare, DNB
Ms. Felicitas Riedl - Life Science Expert, European Investment Bank
Mr. Stephan Christgau - Founding & Managing Partner, Eir Ventures
Dr. Dina Chaya - Partner, NeoMed Management - Advisor, Omega Funds
Dr. Deborah Harland - Partner at SR One - GSK Venture Capital Group
Ms. Rachel Mears - Deputy Director General, Jet Capital
Dr. Ingrid Teigland Akay - Managing Partner, Hadean Ventures
Dr. Joanne M. Hackett - General Partner Healthcare, IZY Capital
Dr. Christina Trojel-Hansen - CEO and Co-Founder - Oscine Therapeutics, in Residence - Arch Venture Partners
Ms. Jeanne Bolger - Corporate Venture Capital Investor, Johnson & Johnson Innovation
The Precision Medicine Revolution has shifted to an evidence-based and ‘proactive’ rather than ‘reactive’ approach and, with this shift, has come the understanding that simply having viable treatments is no longer enough. Improved & earlier detection of disease and the continued identification of new biomarkers are vital steps in improving diagnosis, improving the safety and efficacy of existing medicines, and developing new medicines and targeted therapies. This, of course, highlights the need for innovative diagnostic solutions by small and dynamic companies. At the same time, emerging companies advancing novel, biomarker-based, technology-driven, or digital diagnostics face clear challenges when bringing solutions towards the market: funding is limited, partnering larger players holds potentially unforeseen expectations on how far the SME should have developed, and today’s standards for clinical trial design can act as a hinderance to this sector of the ecosystem. In this session, we aim to get at the root of biomarker and diagnostic-driven SME success, first by minimizing translation gaps between academia, pharma, and diagnostics, then by discussing critical steps in preparation, funding, & merging of strategies across sectors.
Moderator(s): Dr. Abdel Halim - KOL on biomarkers, precision medicine and companion diagnostics, Biomarker Consult
Speaker(s):
Dr. Jutta Heix - Head of International Affairs, Oslo Cancer Cluster - Super Session Chair
Dr. Abdel Halim - KOL on biomarkers, precision medicine and companion diagnostics, Biomarker Consult
Ms. Carolina Haefliger - VP, Head Centre for Genomics Research, AstraZeneca
Ms. Karin Conde-Knape - CVP Global Diabetes, Cardio-Renal and Global Drug Discovery, Novo Nordisk
Dr. Gupta Udatha - Project Coordinator, DIGI-B-CUBE
Mr. Karl Bergman - CEO, Elypta
Dr. Patrick Sobocki - Investment Manager, Industrifonden
In the world of exponential data and digital disruption, there are more stakeholders involved in R&D than ever before. Traditional business models across the drug discovery and development value chain are transitioning at an increasingly rapid pace. Likewise, the diversification of product pipelines has expanded beyond drugs to increasingly include medical devices, big data, and digital tools, through which we can better engage patients and harness the best of medicine. In this session, we take a look at this new field: who is involved, how are they working together, and what does this mean for the future of clinical trials from Academic, Pharmaceutical, Technology, and Regulatory perspectives? Likewise, what are the updates around the new Medical Device Regulations (MDR) – and how should SMEs prepare to take their first big steps towards getting their device(s) on the market?
Moderator(s): Dr. Jessica Shull - European Lead, Digital Therapeutics Alliance
Speaker(s):
Dr. Jessica Shull - European Lead, Digital Therapeutics Alliance
Ms. Sofia Nordgren - Director of Regulatory Affairs, Devicia
Dr. Magnus Björsne - CEO, Astrazeneca BioVentureHub
Mr. Martin Olovsson - CEO and Co-Founder, Ondosis
Dr. Sam Oddsson - Chief Medical Officer & Co-Founder, SidekickHealth
Mr. Torbjörn Hägglöf - Artificial Intelligence Business Sales & Delivery Executive, Cognitive Business Solutions, IBM Global Business Services
CROs and other service providers tend to get a ‘bad rap’ across parts of our industry. Even if they are founded in and driven credible, industry-valuable science, service providers must also survive as businesses by selling their services to ideal partners. And, as we know, challenges can easily arise when sales-meets-science.
In this session, our industry experts from Link Medical discuss how the business challenges of scientifically oriented CROs, as well as how to address the challenges for start-ups and SMEs in finding the “right fit” with the perfect CRO partner.
To support the discussion, one of Link Medical’s California-based clients, will share their experience of how they, as a small company, successfully navigated a sea of CROs to identify their best long-term partner.
From 1st April 2021, company presentations will be available on-demand in the following categories:
From 1st April 2021, company presentations will be available on-demand in the following categories:
